Fennec

Commercial stage specialty pharmaceutical company Fennec Pharmaceuticals (NASDAQ:FENC) (TSX:FRX:CA) said that Adrian Haigh has departed from his position as Fennec’s COO as of June 30, 2024. After nine years as an independent director, in August 2023, Adrian joined the Fennec leadership team as COO. “The company is actively searching for a U.S.-based leader,”Continue Reading